Asundexian Anti-XIa Antithrombotic Shows Promise - The Fritsma Factor

Dec 8 2025

George Fritsma

Select “Bayer’s Asundexian anti XIa antithrombin met primary efficacy and safety endpoints in a landmark phase III OCEANIC-STROKE study for secondary stroke prevention” for their press release presented at ASH 2025.

Comments (0)

Anticoagulant Therapy

No comments here.

Leave a Reply Cancel reply

You must be logged in to post a comment.

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question